Giuseppe Saglio

List of Publications by Year in Descending Order

566 papers	40,513 citations	83 h-index	192 g-index
598 ext. papers	44,727 ext. citations	5.6 avg, IF	6.43 L-index

#	Paper	IF	Citations
566	Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study.. *Frontiers in Oncology*, **2022**, 12, 839915	5.3	0
565	COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. *British Journal of Haematology*, **2021**, 196, 559	4.5	5
564	Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. *Leukemia*, **2021**, 35, 1344-1355	10.7	17
563	Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021. *Haematologica*, **2021**, 106, 1787-1793	6.6	2
562	Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase. *Frontiers in Oncology*, **2021**, 11, 642005	5.3	4
561	Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome. *Cancers*, **2021**, 13,	6.6	8
560	Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-]pyridine Scaffold: SAR of the Biphenyl Moiety. *Journal of Medicinal Chemistry*, **2021**, 64, 5404-5428	8.3	6
559	Alignment of Qx100/Qx200 Droplet Digital (Bio-Rad) and QuantStudio 3D (Thermofisher) Digital PCR for Quantification of BCR-ABL1 in Ph+ Chronic Myeloid Leukemia. *Diseases (Basel, Switzerland)*, **2021**, 9,	4.4	1
558	Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study. *Leukemia*, **2021**, 35, 1814-1816	10.7	0
557	Point: Is there a best duration of deep molecular response to achieve therapy-free remission in chronic myeloid leukaemia?. *British Journal of Haematology*, **2021**, 192, 22-23	4.5	3
556	Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. *Leukemia*, **2021**, 35, 440-453	10.7	36
555	The Giant HECT E3 Ubiquitin Ligase HERC1 Is Aberrantly Expressed in Myeloid Related Disorders and It Is a Novel BCR-ABL1 Binding Partner. *Cancers*, **2021**, 13,	6.6	2
554	The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia. *Cancers*, **2021**, 13,	6.6	4
553	Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. *Frontiers in Oncology*, **2021**, 11, 739171	5.3	1
552	JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy. *Journal of Clinical Medicine*, **2021**, 10,	5.1	1
551	Imatinib: The First-Line CML Therapy. *Hematologic Malignancies*, **2021**, 49-59	0	
550	Novel Multiplex Droplet Digital PCR Assays to Monitor Minimal Residual Disease in Chronic Myeloid Leukemia Patients Showing Atypical Transcripts. *Journal of Clinical Medicine*, **2020**, 9,	5.1	12

549	Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. *Leukemia*, **2020**, 34, 1495-1502	10.7	34
548	Transplantation Induces Profound Changes in the Transcriptional Asset of Hematopoietic Stem Cells: Identification of Specific Signatures Using Machine Learning Techniques. *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
547	Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. *Leukemia*, **2020**, 34, 2260-2261	10.7	37
546	First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis. *Blood Advances*, **2020**, 4, 2723-2735	7.8	17
545	European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. *Leukemia*, **2020**, 34, 966-984	10.7	356
544	Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. *Hematological Oncology*, **2020**, 38, 654-664	1.3	2
543	Prospects for achieving treatment-free remission in chronic myeloid leukaemia. *British Journal of Haematology*, **2020**, 190, 318-327	4.5	11
542	Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia. *British Journal of Haematology*, **2020**, 188, e101-e105	4.5	3
541	Highly Sensitive Detection of Mutations in Acute Myeloid Leukemia. *Journal of Clinical Medicine*, **2020**, 9,	5.1	6
540	Clone wars: co-occurrence of IDH2 R140Q and R172K in myelodysplastic syndromes. *Annals of Hematology*, **2020**, 99, 891-893	3	
539	Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. *Leukemia*, **2020**, 34, 2064-2073	10.7	10
538	Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR4.5: Results from ENESTfreedom. *Blood*, **2020**, 136, 7-8	2.2	1
537	Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 1650-1657	5.6	9
536	A Clinically Applicable Approach to the Classification of B-Cell Non-Hodgkin Lymphomas with Flow Cytometry and Machine Learning. *Cancers*, **2020**, 12,	6.6	9
535	Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR. *Cancers*, **2020**, 12,	6.6	2
534	A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. *Journal of Clinical Medicine*, **2020**, 9,	5.1	2
533	Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic Cells. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	5
532	Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 10978-10986	5.6	14

531	Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. *Blood*, **2020**, 135, 534-541	2.2	37
530	Chronic myeloid leukemia stem cells. *Leukemia*, **2019**, 33, 1543-1556	10.7	70
529	Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia. *Leukemia and Lymphoma*, **2019**, 60, 3330-3332	1.9	5
528	Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	21
527	Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. *Hematological Oncology*, **2019**, 37, 240-252	1.3	5
526	mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways. *Haematologica*, **2019**, 104, 1789-1797	6.6	12
525	Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. *Haematologica*, **2019**, 104, 1589-1596	6.6	38
524	Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis. *Blood*, **2019**, 134, 2924-2924	2.2	20
523	Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib. *Blood*, **2019**, 134, 2932-2932	2.2	3
522	Bone marrow microenvironment: The guardian of leukemia stem cells. *World Journal of Stem Cells*, **2019**, 11, 476-490	5.6	17
521	Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. *Blood Advances*, **2019**, 3, 4280-4290	7.8	40
520	Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. *Journal of Hematology and Oncology*, **2019**, 12, 131	22.4	19
519	Nilotinib in the treatment of chronic myeloid leukemia. *Future Oncology*, **2019**, 15, 953-965	3.6	19
518	A new BCR-ABL1 model as a powerful tool to elucidate the pathogenesis and progression of chronic myeloid leukemia. *Haematologica*, **2019**, 104, 717-728	6.6	4
517	Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. *Journal of Cancer Research and Clinical Oncology*, **2018**, 144, 945-954	4.9	89
516	Dasatinib dose management for the treatment of chronic myeloid leukemia. *Cancer*, **2018**, 124, 1660-1672	6.4	13
515	Prognostic significance of The Wilms' Tumor-1 (WT1) rs16754 polymorphism in acute myeloid leukemia. *Leukemia Research*, **2018**, 67, 6-11	2.7	11
514	Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. *Leukemia Research*, **2018**, 67, 67-74	2.7	7

513	Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient-Physician Perspective. *Clinical Lymphoma, Myeloma and Leukemia*, **2018**, 18, 375-379	2	13
512	Expressional changes in stemness markers post electrochemotherapy in pancreatic cancer cells. *Bioelectrochemistry*, **2018**, 122, 84-92	5.6	4
511	Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib. *British Journal of Haematology*, **2018**, 180, 895-898	4.5	3
510	Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. *Annals of Hematology*, **2018**, 97, 95-100	3	14
509	First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI. *Leukemia and Lymphoma*, **2018**, 59, 1523-1538	1.9	18
508	Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms. *Hematological Oncology*, **2018**, 36, 740-748	1.3	2
507	Present results and future perspectives in optimizing chronic myeloid leukemia therapy. *Haematologica*, **2018**, 103, 928-930	6.6	5
506	Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern. *Blood*, **2018**, 132, 788-788	2.2	4
505	One Size Does Not Fit to All: Intolerant or Resistant CML Patients Could Benefit from Different Ponatinib Starting Dose Strategies. Multicenter Italian Experience. *Blood*, **2018**, 132, 1732-1732	2.2	1
504	The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients. *Blood*, **2018**, 132, 44-44	2.2	6
503	International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. a GIMEMA and HOVON Study. *Blood*, **2018**, 132, 1750-1750	2.2	3
502	Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis. *Blood*, **2018**, 132, 458-458	2.2	2
501	Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. *Blood Cancer Journal*, **2018**, 8, 88	7	11
500	Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors. *Journal of Medicinal Chemistry*, **2018**, 61, 6034-6055	8.3	38
499	IB-At the crossroad between oncogenic and tumor-suppressive signals. *Oncology Letters*, **2017**, 13, 531-534	2.6	17
498	Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. *Leukemia*, **2017**, 31, 1525-1531	10.7	180
497	Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study. *Leukemia and Lymphoma*, **2017**, 58, 2752-2754	1.9	9
496	The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. *American Journal of Hematology*, **2017**, 92, 797-805	7.1	52

495	Modeling myeloproliferative neoplasms: From mutations to mouse models and back again. *Blood Reviews*, **2017**, 31, 139-150	11.1	6
494	Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. *Haematologica*, **2017**, 102, 1530-1536	6.6	12
493	Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia. *Cancer Chemotherapy and Pharmacology*, **2017**, 79, 767-773	3.5	11
492	Mimicking the Acute Myeloid Leukemia Niche for Molecular Study and Drug Screening. *Tissue Engineering - Part C: Methods*, **2017**, 23, 72-85	2.9	22
491	Altered Erythropoiesis in Mouse Models of Type 3 Hemochromatosis. *BioMed Research International*, **2017**, 2017, 2408941	3	6
490	A novel assay to detect calreticulin mutations in myeloproliferative neoplasms. *Oncotarget*, **2017**, 8, 6399-64055	3.3	
489	CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report. *Stem Cell Investigation*, **2017**, 4, 57	5.1	11
488	Specific Monoclonal Antibody Against Bcr/Abl Out-of-Frame Alternative Proteins as Diagnostic Tool in Chronic Myelogenous Leukemia Patients. *Monoclonal Antibodies in Immunodiagnosis and Immunotherapy*, **2017**, 36, 149-156	1.9	
487	5'UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia. *Journal of Hematology and Oncology*, **2017**, 10, 18	22.4	23
486	Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. *Annals of Hematology*, **2017**, 96, 1303-1313	3	12
485	Clinical significance of TFR2 and EPOR expression in bone marrow cells in myelodysplastic syndromes. *British Journal of Haematology*, **2017**, 176, 491-495	4.5	5
484	Epha3 acts as proangiogenic factor in multiple myeloma. *Oncotarget*, **2017**, 8, 34298-34309	3.3	16
483	Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones. *Oncotarget*, **2017**, 8, 35508-35522	3.3	40
482	The and polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. *Oncotarget*, **2017**, 8, 88021-88033	3.3	10
481	Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia. *Current Drug Targets*, **2017**, 18, 389-395	3	3
480	The biology of CML supports second-generation TKIs as frontline treatment. *Clinical Advances in Hematology and Oncology*, **2017**, 15, 302-307	0.6	1
479	Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. *Leukemia*, **2016**, 30, 57-64	10.7	78
478	Characterization of human mitochondrial ferritin promoter: identification of transcription factors and evidences of epigenetic control. *Scientific Reports*, **2016**, 6, 33432	4.9	12

477	The Choice of First-Line Chronic Myelogenous Leukemia Treatment. *Hematologic Malignancies*, **2016**, 41-54	0	
476	The targetable role of herpes virus-associated ubiquitin-specific protease (HAUSP) in p190 BCR-ABL leukemia. *Oncology Letters*, **2016**, 12, 3123-3126	2.6	3
475	Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. *Haematologica*, **2016**, 101, 1200-1207	6.6	19
474	Can chronic myeloid leukaemia in children and adolescents be successfully treated without haematopoietic stem cell transplant? A single centre experience. *British Journal of Haematology*, **2016**, 173, 749-53	4.5	
473	Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. *Journal of Clinical Oncology*, **2016**, 34, 2333-40	2.2	485
472	Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. *Leukemia and Lymphoma*, **2016**, 57, 1517-26	1.9	2
471	Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. *Leukemia*, **2016**, 30, 1044-54	10.7	497
470	Dasatinib first-line: Multicentric Italian experience outside clinical trials. *Leukemia Research*, **2016**, 40, 24-9	2.7	4
469	Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. *Blood*, **2016**, 128, 3070-3070	2.2	7
468	ENESTPath: A Phase 3 Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with Imatinib: 24-Month Analysis of the First 300 Patients in the Induction/Consolidation Phase. *Blood*, **2016**, 128, 3094-3094	2.2	9
467	Early molecular response in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or imatinib (IM) from DASISION.. *Journal of Clinical Oncology*, **2016**, 34, 7055-7055	2.2	1
466	The BCR-ABL/NF-Β signal transduction network: a long lasting relationship in Philadelphia positive Leukemias. *Oncotarget*, **2016**, 7, 66287-66298	3.3	18
465	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. *Oncotarget*, **2016**, 7, 80083-80090	3.3	21
464	Variable but consistent pattern of Meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection. *Oncotarget*, **2016**, 7, 74082-74096	3.3	7
463	Recommendations for the Management of CML in the Era of Second-Generation TKIs **2016**, 131-145		
462	Mechanisms of p53 Functional De-Regulation: Role of the IΒ-Δp53 Complex. *International Journal of Molecular Sciences*, **2016**, 17,	6.3	7
461	The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase. *BMC Cancer*, **2016**, 16, 314	4.8	9
460	A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. *PLoS ONE*, **2016**, 11, e0162866	3.7	66

459	Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. *American Journal of Hematology*, **2016**, 91, 617-22	7.1	10
458	Transferrin Receptor 2 Dependent Alterations of Brain Iron Metabolism Affect Anxiety Circuits in the Mouse. *Scientific Reports*, **2016**, 6, 30725	4.9	13
457	In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. *BMC Cancer*, **2016**, 16, 572	4.8	15
456	Ponatinib for chronic myeloid leukaemia: future perspectives. *Lancet Oncology, The*, **2016**, 17, 546-7	21.7	8
455	Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16 Suppl, S96-S100	2	11
454	Chronic myeloid leukemia: reminiscences and dreams. *Haematologica*, **2016**, 101, 541-58	6.6	61
453	Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. *Leukemia*, **2016**, 30, 1844-52	10.7	40
452	BCR-ABL1 mutation □ponatinib resistance. *Blood*, **2016**, 127, 666-7	2.2	3
451	Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. *American Journal of Hematology*, **2016**, 91, 869-74	7.1	98
450	The Wilms' tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy. *Cancer Medicine*, **2016**, 5, 1650-3	4.8	7
449	Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. *Cancer*, **2016**, 122, 1398-407	6.4	35
448	BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. *Leukemia*, **2015**, 29, 1832-8	10.7	49
447	Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia. *Leukemia and Lymphoma*, **2015**, 56, 2105-13	1.9	18
446	Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. *British Journal of Haematology*, **2015**, 170, 398-407	4.5	23
445	Morgana acts as an oncosuppressor in chronic myeloid leukemia. *Blood*, **2015**, 125, 2245-53	2.2	17
444	Milestones and monitoring. *Current Hematologic Malignancy Reports*, **2015**, 10, 167-72	4.4	12
443	The choice of first-line chronic myelogenous leukemia treatment. *Annals of Hematology*, **2015**, 94 Suppl 2, S123-31	3	20
442	Update on emerging treatments for chronic myeloid leukemia. *Expert Opinion on Emerging Drugs*, **2015**, 20, 183-96	3.7	19

441	Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. *Haematologica*, **2015**, 100, 1146-50	6.6	29
440	Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. *Leukemia*, **2015**, 29, 1823-31	10.7	64
439	Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1852-5	4.7	3
438	HAUSP compartmentalization in chronic myeloid leukemia. *European Journal of Haematology*, **2015**, 94, 318-21	3.8	10
437	Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. *Leukemia and Lymphoma*, **2015**, 56, 1938-48	1.9	5
436	Development of cellular and humoral response against WT1 protein vaccination in mice. *American Journal of Hematology*, **2015**, 90, E193-4	7.1	
435	Treatment-free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia. *British Journal of Haematology*, **2015**, 168, 305-8	4.5	15
434	Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. *Blood*, **2015**, 125, 499-503	2.2	90
433	Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. *Blood*, **2015**, 125, 2771-8	2.2	68
432	A comparative study of myocardial molecular phenotypes of two tfr2□hull mice: role in ischemia/reperfusion. *BioFactors*, **2015**, 41, 360-71	6.1	10
431	The Role of PTEN in Myeloid Malignancies. *Hematology Reports*, **2015**, 7, 5844	0.9	26
430	Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias. *Advances in Hematology*, **2015**, 2015, 612567	1.5	8
429	Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISH. *Biomarker Research*, **2015**, 3, 15	8	5
428	Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. *Leukemia*, **2015**, 29, 999-1003	10.7	229
427	BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation. *Cell Cycle*, **2015**, 14, 973-9	4.7	21
426	Differences among young adults, adults and elderly chronic myeloid leukemia patients. *Annals of Oncology*, **2015**, 26, 185-192	10.3	48
425	Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System. *American Journal of Hematology*, **2015**, 90, E66-72	7.1	42
424	Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP). *Blood*, **2015**, 126, 2781-2781	2.2	9

423	Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase. *Blood*, **2015**, 126, 4040-4040	2.2	6
422	mTOR pathway activation in multiple myeloma cell lines and primary tumour cells: pomalidomide enhances cytoplasmic-nuclear shuttling of mTOR protein. *Oncoscience*, **2015**, 2, 382-94	0.8	8
421	New alternative splicing BCR/ABL-OOF shows an oncogenic role by lack of inhibition of BCR GTPase activity and an increased of persistence of Rac activation in chronic myeloid leukemia. *Oncoscience*, **2015**, 2, 880-91	0.8	3
420	Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes IB-mediated p53 nuclear exclusion. *Oncotarget*, **2015**, 6, 25217-25	3.3	14
419	Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. *Leukemia Research*, **2014**, 38, 236-42	2.7	22
418	Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). *Blood*, **2014**, 123, 494-500	2.2	309
417	Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial. *Annals of Hematology*, **2014**, 93, 1401-12	3	22
416	Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013. *Critical Reviews in Oncology/Hematology*, **2014**, 90, 181-9	7	4
415	Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper. *Leukemia Research*, **2014**, 38, 155-60	2.7	24
414	Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. *Haematologica*, **2014**, 99, 1204-11	6.6	38
413	Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. *Blood*, **2014**, 123, 1353-60	2.2	196
412	Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. *Blood*, **2014**, 123, 2317-24	2.2	137
411	BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia. *PLoS ONE*, **2014**, 9, e110682	3.7	13
410	The erythroid function of transferrin receptor 2 revealed by Tmprss6 inactivation in different models of transferrin receptor 2 knockout mice. *Haematologica*, **2014**, 99, 1016-21	6.6	29
409	BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP. *Leukemia*, **2014**, 28, 1326-33	10.7	51
408	Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia. *Therapeutic Drug Monitoring*, **2014**, 36, 410-2	3.2	9
407	Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia. *Expert Opinion on Biological Therapy*, **2014**, 14, 287-99	5.4	31
406	Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056). *Blood*, **2014**, 124, 152-152	2.2	41

405	The Observed and Expected Incidence of Cardiovascular (CV) Ischemic Events in Dasatinib (DAS)-Treated Patients (pts) Across a Clinical Trial Program. *Blood*, **2014**, 124, 4534-4534	2.2	4
404	ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM).. *Journal of Clinical Oncology*, **2014**, 32, 7073-7073	2.2	19
403	Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath.. *Journal of Clinical Oncology*, **2014**, 32, TPS7124-TPS7124	2.2	10
402	Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. *Leukemia and Lymphoma*, **2013**, 54, 1151-8	1.9	8
401	Design and application of a novel PNA probe for the detection at single cell level of JAK2V617F mutation in Myeloproliferative Neoplasms. *BMC Cancer*, **2013**, 13, 348	4.8	3
400	Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. *BMC Cancer*, **2013**, 13, 173	4.8	13
399	Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. *Leukemia*, **2013**, 27, 1310-5	10.7	160
398	Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13 Suppl 2, S272-5	2	4
397	Identifying the time to change BCR-ABL inhibitor therapy in patients with chronic myeloid leukemia. *Acta Haematologica*, **2013**, 130, 268-78	2.7	8
396	Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. *Leukemia*, **2013**, 27, 107-12	10.7	169
395	Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. *Leukemia Research*, **2013**, 37, 520-30	2.7	15
394	Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. *Leukemia*, **2013**, 27, 907-13	10.7	22
393	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. *Blood*, **2013**, 122, 872-84	2.2	1413
392	Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. *Blood*, **2013**, 121, 3703-8	2.2	73
391	Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. *Haematologica*, **2013**, 98, 193-200	6.6	83
390	Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response. *Blood*, **2013**, 122, 653-653	2.2	17
389	ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes. *Blood*, **2013**, 122, 92-92	2.2	26
388	Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update.. *Journal of Clinical Oncology*, **2013**, 31, 7052-7052	2.2	5

387	Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd.. *Journal of Clinical Oncology*, **2013**, 31, 7054-7054	2.2	1
386	RBC-transfusion guidelines update. *Leukemia Research*, **2012**, 36, 659-60	2.7	5
385	HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). *Journal of Pharmaceutical and Biomedical Analysis*, **2012**, 59, 109-16	3.5	53
384	Suboptimal responses in chronic myeloid leukemia: implications and management strategies. *Cancer*, **2012**, 118, 1181-91	6.4	17
383	Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. *Haematologica*, **2012**, 97, 907-14	6.6	48
382	Two novel mutations in the tmprss6 gene associated with iron-refractory iron-deficiency anaemia (irida) and partial expression in the heterozygous form. *British Journal of Haematology*, **2012**, 158, 668-72	4.5	18
381	Chronic myeloid leukemia: state of the art in 2012. *Current Oncology Reports*, **2012**, 14, 379-86	6.3	7
380	Adherence to BCR-ABL inhibitors: issues for CML therapy. *Clinical Lymphoma, Myeloma and Leukemia*, **2012**, 12, 223-9	2	27
379	Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. *Cancer Chemotherapy and Pharmacology*, **2012**, 70, 345-50	3.5	20
378	Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. *Blood*, **2012**, 120, 761-7	2.2	85
377	Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. *Leukemia and Lymphoma*, **2012**, 53, 2351-61	1.9	68
376	Standardized definitions of molecular response in chronic myeloid leukemia. *Leukemia*, **2012**, 26, 2172-5	10.7	293
375	Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. *Blood*, **2012**, 119, 5963-71	2.2	57
374	Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. *Leukemia*, **2012**, 26, 2197-203	10.7	335
373	Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. *European Journal of Clinical Pharmacology*, **2012**, 68, 723-33	2.8	74
372	Molecular pathways: BCR-ABL. *Clinical Cancer Research*, **2012**, 18, 930-7	12.9	156
371	Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. *Journal of Clinical Oncology*, **2012**, 30, 4323-9	2.2	78
370	Second-generation TKIs: which and when?. *Leukemia Supplements*, **2012**, 1, S40-2	75	1

369	BCR/ABL1 fusion transcripts generated from alternative splicing: implications for future targeted therapies in Ph+ leukaemias. *Current Molecular Medicine*, **2012**, 12, 547-65	2.5	6
368	Practical monitoring of chronic myelogenous leukemia: when to change treatment. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2012**, 10, 121-9	7.3	7
367	Immunologic evaluation of peptides derived from BCR/ABL-out-of-frame fusion protein in HLA A2.1 transgenic mice. *Journal of Immunotherapy*, **2012**, 35, 321-8	5	4
366	Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients). *Blood*, **2012**, 120, 167-167	2.2	10
365	Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data. *Blood*, **2012**, 120, 1675-1675	2.2	14
364	Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP). *Blood*, **2012**, 120, 1676-1676	2.2	13
363	Incidence of Hyperglycemia by 3 Years in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib (NIL) or Imatinib (IM) in ENESTnd. *Blood*, **2012**, 120, 1686-1686	2.2	10
362	High Predictive Value of the Revised International Prognostic Scoring System (IPSS-R): An External Analysis of 646 Patients From a Multiregional Italian MDS Registry. *Blood*, **2012**, 120, 1702-1702	2.2	1
361	Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u).. *Journal of Clinical Oncology*, **2012**, 30, 6509-6509	2.2	2
360	Detection of an Unbalanced Ratio Between WT1 Isoforms in Acute Myeloid Leukemia and Its Correlation with Molecular Abnormalities.. *Blood*, **2012**, 120, 2500-2500	2.2	
359	Single-Nucleotide Polymorphisms of ABCB1 Gene Influence Intracellular Concentrations of Dasatinib. *Blood*, **2012**, 120, 4903-4903	2.2	1
358	A Sensitive Replicate RQ-PCR of BCR ABL Transcripts Suggests That A Large Portion of Long Term Post Allogeneic SCT CML Patients Are in Deep MR and May Therefore Be Cured From Their Disease. *Blood*, **2012**, 120, 1690-1690	2.2	
357	Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. *Leukemia and Lymphoma*, **2011**, 52, 896-904	1.9	88
356	Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. *European Journal of Cancer*, **2011**, 47, 814-8	7.5	14
355	BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. *Blood*, **2011**, 118, 1208-15	2.2	395
354	Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. *Lancet Oncology, The*, **2011**, 12, 841-51	21.7	383
353	Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. *Blood*, **2011**, 117, 5591-9	2.2	78
352	Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. *Blood*, **2011**, 117, 1141-5	2.2	296

351	Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. *Blood*, **2011**, 117, 6793-800	2.2	66
350	SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. *Blood*, **2011**, 118, 3634-44	2.2	41
349	Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. *Blood*, **2011**, 118, 5697-700	2.2	40
348	Thalidomide after lenalidomide: a possible treatment regimen in relapse refractory multiple myeloma patients. *British Journal of Haematology*, **2011**, 152, 108-10	4.5	6
347	Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes. *European Journal of Haematology*, **2011**, 87, 409-18	3.8	12
346	Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. *Cancer*, **2011**, 117, 1800-11	6.4	61
345	What are RBC-transfusion-dependence and -independence?. *Leukemia Research*, **2011**, 35, 8-11	2.7	67
344	Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes. *Leukemia Research*, **2011**, 35, 504-7	2.7	11
343	A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. *Journal of Chromatographic Science*, **2011**, 49, 753-7	1.4	29
342	Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. *Clinical Cancer Research*, **2011**, 17, 1674-83	12.9	46
341	Characterization of a monoclonal antibody specific for novel Bcr/Abl out-of-frame fusion proteins. *Hybridoma*, **2011**, 30, 261-9		3
340	Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial). *Blood*, **2011**, 118, 2756-2756	2.2	7
339	Dasatinib and Imatinib-Induced Reductions in BCR-ABL Transcript Levels Below 10% At 3 Months Are Associated with Improved Responses in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Analysis of Molecular Response Kinetics in the DASISION Trial. *Blood*, **2011**, 118, 2767-2767	2.2	9
338	Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,. *Blood*, **2011**, 118, 3770-3770	2.2	4
337	Nilotinib Versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-up. *Blood*, **2011**, 118, 452-452	2.2	8
336	Five-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib.. *Journal of Clinical Oncology*, **2011**, 29, 6512-6512	2.2	9
335	Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients. *Leukemia*, **2010**, 24, 66-73	10.7	22
334	NPM1 deletion is associated with gross chromosomal rearrangements in leukemia. *PLoS ONE*, **2010**, 5, e12855	3.7	16

333	Iron chelation therapy in myelodysplastic syndromes. *Advances in Hematology*, **2010**, 2010, 756289	1.5	9
332	Emerging drugs for chronic myeloid leukemia. *Expert Opinion on Emerging Drugs*, **2010**, 15, 175-84	3.7	2
331	Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. *Haematologica*, **2010**, 95, 1308-16	6.6	103
330	Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. *Blood*, **2010**, 116, e111-7	2.2	120
329	First-line therapy for chronic myeloid leukemia: new horizons and an update. *Clinical Lymphoma, Myeloma and Leukemia*, **2010**, 10, 169-76	2	13
328	Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. *Journal of Clinical Oncology*, **2010**, 28, 2748-54	2.2	48
327	Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia?. *Seminars in Hematology*, **2010**, 47, 319-26	4	9
326	Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. *Expert Review of Hematology*, **2010**, 3, 665-73	2.8	32
325	Comparison of 3 Tfr2-deficient murine models suggests distinct functions for Tfr2-alpha and Tfr2-beta isoforms in different tissues. *Blood*, **2010**, 115, 3382-9	2.2	53
324	The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. *Haematologica*, **2010**, 95, 1415-9	6.6	39
323	Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. *New England Journal of Medicine*, **2010**, 362, 2251-9	59.2	1266
322	Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. *Cancer*, **2010**, 116, 3852-61	6.4	96
321	ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP). *Blood*, **2010**, 116, 207-207	2.2	17
320	Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd. *Blood*, **2010**, 116, 2291-2291	2.2	9
319	Patients with Chronic Myeloid Leukemia In Chronic Phase Carrying More Than One BCR-ABL Kinase Domain Mutation Exhibit Poorer Response Rates and Outcomes to Second-Line Dasatinib Compared to Those with No or Only One BCR-ABL Mutation. *Blood*, **2010**, 116, 2297-2297	2.2	1
318	Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial.. *Blood*, **2010**, 116, 3430-3430	2.2	14
317	Lymphocytosis Following First-Line Treatment for CML In Chronic Phase with Dasatinib Is Associated with Improved Responses: A Comparison with Imatinib. *Blood*, **2010**, 116, 358-358	2.2	6
316	Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial. *Blood*, **2010**, 116, 359-359	2.2	12

315	Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year.. *Journal of Clinical Oncology*, **2010**, 28, 6501-6501	2.2	9
314	Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily.. *Journal of Clinical Oncology*, **2010**, 28, 6512-6512	2.2	3
313	Association of lymphocytosis following treatment with dasatinib with response and outcome.. *Journal of Clinical Oncology*, **2010**, 28, 6553-6553	2.2	3
312	Incidence and Mortality of Second Malignancies In 559 Patients with Chronic Myeloid Leukemia (CML) Treated with Imatinib Frontline: Data From the GIMEMA CML Working Party. *Blood*, **2010**, 116, 2281-2281	2.2	
311	One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (65 years) Ph+ CML Patients EudraCT Number 2007 005102-42, ClinicalTrials.Gov NCT 00858806.. *Blood*, **2010**, 116, 3412-3412	2.2	
310	The best frontline therapy for CML: imatinib?. *Clinical Advances in Hematology and Oncology*, **2010**, 8, 240-2	0.6	
309	Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia. *Journal of Oncology*, **2009**, 2009, 867380	4.5	15
308	Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemia. *Leukemia and Lymphoma*, **2009**, 50, 1564-5	1.9	0
307	Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response. *Clinical Cancer Research*, **2009**, 15, 1059-63	12.9	27
306	Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. *Journal of Clinical Oncology*, **2009**, 27, 4204-10	2.2	248
305	Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. *European Journal of Haematology*, **2009**, 82, 61-8	3.8	66
304	HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma. *International Journal of Hematology*, **2009**, 90, 392-396	2.3	29
303	Herpetic leg paralysis and abdominal ileus in a patient with idiopathic myelofibrosis. *Internal and Emergency Medicine*, **2009**, 4, 65-6	3.7	1
302	Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose. *Cancer Chemotherapy and Pharmacology*, **2009**, 63, 1161-3	3.5	2
301	The molecular anatomy of the FIP1L1-PDGFRA fusion gene. *Leukemia*, **2009**, 23, 271-8	10.7	16
300	Harmonization of molecular monitoring of CML therapy in Europe. *Leukemia*, **2009**, 23, 1957-63	10.7	170
299	New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2009**, 877, 1721-6	3.2	82
298	Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). *Blood*, **2009**, 114, 2159-67	2.2	180

297	IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. *Journal of Clinical Oncology*, **2009**, 27, 5202-7	2.2	245
296	Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. *Journal of Clinical Oncology*, **2009**, 27, 6041-51	2.2	1019
295	Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. *Journal of Clinical Oncology*, **2009**, 27, 5195-201	2.2	337
294	Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice. *Cancer Letters*, **2009**, 276, 61-7	9.9	7
293	CML: a model for targeted therapy. *Best Practice and Research in Clinical Haematology*, **2009**, 22, 285-94	4.2	11
292	Identification of a novel mutation in the L ferritin iron-responsive element causing hereditary hyperferritinemia-cataract syndrome. *Acta Haematologica*, **2009**, 122, 223-5	2.7	4
291	Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. *Leukemia and Lymphoma*, **2009**, 50, 114-8	1.9	6
290	The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. *Haematologica*, **2009**, 94, 205-12	6.6	54
289	Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. *Blood*, **2009**, 113, 3428-34	2.2	53
288	Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. *Blood*, **2009**, 113, 4497-504	2.2	158
287	Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. *Blood*, **2009**, 114, 4933-8	2.2	176
286	FOXO transcription factor activity is partially retained in quiescent CML stem cells and induced by tyrosine kinase inhibitors in CML progenitor cells. *Blood*, **2009**,	2.2	5
285	Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.. *Blood*, **2009**, 114, 1129-1129	2.2	15
284	The Oncogenic Kinase Bcr-Abl Directly Regulates Splicing of BclX through a Quaternary Complex Coordinated by Nck-Beta and Sam-68 Adapter Proteins.. *Blood*, **2009**, 114, 2171-2171	2.2	1
283	The Combination of Interferon-Alpha with Imatinib in Early Chronic Phase Chronic Myeloid Leukemia Patients Induces a Significant Improvement of the Molecular Responses in the First Two Years of Treatment: Results From Three Studies From the GIMEMA CML Working Party.. *Blood*, **2009**, 114, 2192-2192	2.2	2
282	Sequential Therapy with IMID's in Relapsed-Refractory Multiple Myeloma Patients.. *Blood*, **2009**, 114, 2888-2888	2.2	2
281	Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP).. *Blood*, **2009**, 114, 3292-3292	2.2	3
280	Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial. *Blood*, **2009**, 114, LBA-1-LBA-1	2.2	15

279	SIRT1 Activator 3 Potently Induces Apoptosis in Multiple Myeloma Cell Lines and in Primary Human Multiple Myeloma Cells.. *Blood*, **2009**, 114, 3845-3845	2.2	
278	Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations. *Leukemia*, **2008**, 22, 1234-40	10.7	38
277	PML targeting eradicates quiescent leukaemia-initiating cells. *Nature*, **2008**, 453, 1072-8	50.4	455
276	Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. *Leukemia*, **2008**, 22, 96-102	10.7	87
275	Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. *Acta Haematologica*, **2008**, 120, 70-4	2.7	87
274	Detection of humoral immune responses against WT1 antigen in patients affected by different hematological malignancies. *Acta Haematologica*, **2008**, 120, 47-50	2.7	2
273	Monitoring treatment of chronic myeloid leukemia. *Haematologica*, **2008**, 93, 161-9	6.6	78
272	NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. *Haematologica* , **2008**, 93, 439-42	6.6	66
271	Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. *Haematologica*, **2008**, 93, 1792-6	6.6	74
270	Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. *Journal of Clinical Oncology*, **2008**, 26, 106-11	2.2	40
269	Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. *Haematologica*, **2008**, 93, 1814-21	6.6	34
268	New therapeutic approaches and prognostic factors in chronic myeloid leukemia. *Leukemia and Lymphoma*, **2008**, 49, 625-8	1.9	10
267	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. *Blood*, **2008**, 111, 1834-9	2.2	255
266	Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. *Blood*, **2008**, 112, 3330-8	2.2	306
265	Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome. *Haematologica*, **2008**, 93, 770-4	6.6	49
264	Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. *Haematologica*, **2008**, 93, 921-4	6.6	90
263	Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. *Haematologica*, **2008**, 93, 1017-24	6.6	16
262	Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. *European Journal of Haematology*, **2008**, 80, 168-76	3.8	183

261	Molecular monitoring in patients with chronic myelogenous leukemia. *Current Hematologic Malignancy Reports*, **2008**, 3, 65-71	4.4	
260	Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis. *Neurological Sciences*, **2008**, 29, 185-7	3.5	10
259	Thalidomide-induced partial stable remission in a case of refractory progressive B Cell Chronic Lymphoid Leukemia. *Leukemia Research*, **2008**, 32, 506-7	2.7	2
258	Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. *Blood*, **2008**, 112, 3847-55	2.2	95
257	High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party. *Blood*, **2008**, 112, 181-181	2.2	16
256	Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line. *Blood*, **2008**, 112, 185-185	2.2	8
255	Dasatinib Time to and Durability of Major and Complete Cytogenetic Response (MCyR and CCyR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). *Blood*, **2008**, 112, 450-450	2.2	13
254	Nilotinib 800 mg daily as first line treatment of chronic myeloid leukemia in early chronic phase: results of a phase II trial of the GIMEMA CML Working Party. *Journal of Clinical Oncology*, **2008**, 26, 7054-7054	2.2	2
253	Prognostic Significance of Molecular Follow-up by Qualitative and Real-Time Quantitative Reverse-Transcriptase Polymerase Chain Reaction in TEL/AML1Positive Childhood Acute Lymphoblastic Leukemia. *Clinical Leukemia*, **2007**, 1, 298-303		
252	Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study. *Haematologica*, **2007**, 92, 1721-2	6.6	14
251	CD7/CD56-positive acute myeloid leukemias are characterized by constitutive phosphorylation of the NF-kB subunit p65 at Ser536. *Leukemia*, **2007**, 21, 1305-6	10.7	10
250	WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia. *Leukemia*, **2007**, 21, 1442-50	10.7	21
249	Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements. *Leukemia*, **2007**, 21, 1481-7	10.7	25
248	Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14). *Cancer Genetics and Cytogenetics*, **2007**, 173, 51-6		5
247	A young man with persistent eosinophilia. *Internal and Emergency Medicine*, **2007**, 2, 107-12	3.7	2
246	Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches. *Cancer Research*, **2007**, 67, 5300-7	10.1	37
245	Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. *Haematologica*, **2007**, 92, 401-4	6.6	150
244	The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. *Haematologica*, **2007**, 92, 1173-9	6.6	177

243	An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR. *Haematologica*, **2007**, 92, 970-3	6.6	41
242	Nuclear factor kB as a target for new drug development in myeloid malignancies. *Haematologica*, **2007**, 92, 1224-9	6.6	74
241	Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. *Haematologica*, **2007**, 92, 101-5	6.6	49
240	Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. *Blood*, **2007**, 109, 4635-40	2.2	167
239	Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. *Blood*, **2007**, 109, 3207-13	2.2	354
238	Bcr-Abl and Signal Transduction **2007**, 15-35		
237	Kinetics of Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients May Predict Persistent Polymerase Chain Reaction Negativity after Imatinib Discontinuation.. *Blood*, **2007**, 110, 1956-1956	2.2	
236	Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells. *Cancer*, **2006**, 106, 1188-96	6.4	33
235	NF-kB inhibition as a strategy to enhance etoposide-induced apoptosis in K562 cell line. *American Journal of Hematology*, **2006**, 81, 938-45	7.1	38
234	Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. *Journal of Clinical Oncology*, **2006**, 24, 454-9	2.2	34
233	Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients. *Annals of Oncology*, **2006**, 17, 495-502	10.3	20
232	Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. *Clinical Cancer Research*, **2006**, 12, 3037-42	12.9	78
231	Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. *Clinical Cancer Research*, **2006**, 12, 7374-9	12.9	405
230	Very low doses of thalidomide as single agent in relapsed/refractory multiple myeloma. *Acta Haematologica*, **2006**, 116, 70-1	2.7	1
229	Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. *New England Journal of Medicine*, **2006**, 355, 2408-17	59.2	2811
228	Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. *Journal of Clinical Oncology*, **2006**, 24, e51-2	2.2	52
227	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. *Blood*, **2006**, 108, 28-37	2.2	977
226	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. *Blood*, **2006**, 108, 1809-20	2.2	998

225	Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. *Blood*, **2006**, 107, 473-9	2.2	93
224	BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. *Blood*, **2006**, 107, 1591-8	2.2	44
223	Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. *Blood*, **2006**, 108, 1999-2005	2.2	146
222	Occurrence of the same chromosome abnormalities in Ph+ and Ph- cells in chronic myeloid leukaemia. Evidence of a secondary origin of the Ph chromosome?. *British Journal of Haematology*, **2006**, 135, 265-6	4.5	10
221	JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders. *British Journal of Haematology*, **2006**, 135, 267-8	4.5	29
220	The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. *Leukemia*, **2006**, 20, 61-7	10.7	84
219	Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. *Leukemia*, **2006**, 20, 1103-8	10.7	234
218	Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. *Leukemia*, **2006**, 20, 1925-30	10.7	164
217	Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes. *Annals of the New York Academy of Sciences*, **2006**, 1089, 411-23	6.5	7
216	Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management. *Hematological Oncology*, **2006**, 24, 196-204	1.3	28
215	WT1 overexpression in acute myeloid leukemia and myelodysplastic syndromes. *Methods in Molecular Medicine*, **2006**, 125, 199-211		9
214	JAK2V617F Mutation in Leukaemic Transformation of Philadelphia Negative Chronic Myeloproliferative Disorders.. *Blood*, **2006**, 108, 3605-3605	2.2	
213	Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. *New England Journal of Medicine*, **2005**, 352, 254-66	59.2	1374
212	A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. *Blood*, **2005**, 105, 3434-41	2.2	161
211	Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?. *Blood*, **2005**, 105, 904; author reply 905	2.2	8
210	Independent clones at separable stages of differentiation, bearing different GATA1 mutations, in the same TMD patient with Down syndrome. *Blood*, **2005**, 106, 1887-8	2.2	8
209	Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. *Leukemia*, **2005**, 19, 628-35	10.7	77
208	Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. *Cancer*, **2005**, 104, 101-9	6.4	86

207	ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. *Journal of Clinical Oncology*, **2005**, 23, 4100-9	2.2	308
206	WT1 overexpression: a clinically useful marker in acute and chronic myeloid leukemias. *Hematology*, **2005**, 10 Suppl 1, 76-8	2.2	3
205	Better Molecular Response (MR) to Imatinib (IM) in Early Chronic Phase (CP) Versus Late CP Chronic Myeloid Leukemia (CML) Patients (pts) in Complete Cytogenetic Response (CCR): A Comparison at 24 Months of 2 Clinical Trials of the GIMEMA Working Party on CML on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML).. *Blood*, **2005**, 106, 1096-1096	2.2	1
204	Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia (CML) on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML).. *Blood*, **2005**, 106, 1100-1100	2.2	
203	Retrospective comparison of qualitative and quantitative reverse transcriptase polymerase chain reaction in diagnosing and monitoring the ALL1-AF4 fusion transcript in patients with acute lymphoblastic leukaemia. *Leukemia*, **2004**, 18, 1824-30	10.7	5
202	Myelodysplastic syndromes. *Annals of the New York Academy of Sciences*, **2004**, 1028, 400-8	6.5	7
201	Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia. *Annals of the New York Academy of Sciences*, **2004**, 1028, 423-31	6.5	17
200	Abl: the prototype of oncogenic fusion proteins. *Cellular and Molecular Life Sciences*, **2004**, 61, 2897-911	10.3	18
199	Insertions generating the 5'RUNX1/3'CBFA2T1 gene in acute myeloid leukemia cases show variable breakpoints. *Genes Chromosomes and Cancer*, **2004**, 41, 86-91	5	19
198	Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. *Cancer*, **2004**, 101, 979-88	6.4	30
197	Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. *Clinical Chemistry*, **2004**, 50, 1205-13	5.5	109
196	WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. *Acta Haematologica*, **2004**, 112, 79-84	2.7	80
195	A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma. *Clinical Lymphoma and Myeloma*, **2004**, 5, 50-5		28
194	Usefulness of the quantitative assessment of PRV-1 gene expression for the diagnosis of polycythemia vera and essential thrombocythemia patients. *Blood*, **2004**, 103, 2428; author reply 2429	2.2	7
193	Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. *Blood*, **2004**, 103, 2284-90	2.2	60
192	Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. *Blood*, **2004**, 104, 4245-51	2.2	85
191	Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRA Rearrangement Can Be Effectively Treated with Imatinib.. *Blood*, **2004**, 104, 1504-1504	2.2	1
190	European Multicenter Experience on Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRA Rearrangement treated with Imatinib.. *Blood*, **2004**, 104, 1507-1507	2.2	1

189	Molecular Heterogeneity of the FIP1L1-PDGFRA Fusion Gene in Chronic Eosinophilic Leukemia (CEL) and Systemic Mastocytosis with Eosinophilia (SME): A Study of 43 Cases.. *Blood*, **2004**, 104, 2428-2428	2.2	2
188	Imatinib in the Treatment of CML Patients ≥65 Years Old in Late Chronic Phase: Results of a Phase II Study of the GIMEMA CML Working Party.. *Blood*, **2004**, 104, 2935-2935	2.2	
187	Heterogeneous Chromosomal Mechanisms Generating the 5?RUNX1/3?CBFA2T1 Gene in Acute Myeloid Leukemia.. *Blood*, **2004**, 104, 4272-4272	2.2	
186	Glivec and CML: a lucky date. *Journal of Biological Regulators and Homeostatic Agents*, **2004**, 18, 246-51	0.7	8
185	Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. *New England Journal of Medicine*, **2003**, 348, 994-1004	59.2	2797
184	Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome. *Blood*, **2003**, 102, 2014-20	2.2	35
183	Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection. *Blood*, **2003**, 102, 773-4; author reply 774	2.2	32
182	Down-modulation of the C/EBPalpha transcription factor in core binding factor acute myeloid leukemias. *Blood*, **2003**, 102, 2705-6	2.2	26
181	E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. *British Journal of Haematology*, **2003**, 120, 484-7	4.5	54
180	Reply to Martinelli et al. *Leukemia*, **2003**, 17, 651-652	10.7	
179	Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. *Leukemia*, **2003**, 17, 2318-57	10.7	1188
178	Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. *Leukemia*, **2003**, 17, 2474-86	10.7	717
177	Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy. *Seminars in Hematology*, **2003**, 40, 37-41	4	10
176	Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. *Journal of Clinical Oncology*, **2003**, 21, 1988-95	2.2	125
175	Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy. *Seminars in Hematology*, **2003**, 40, 37-41	4	
174	Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. *Haematologica*, **2003**, 88, 256-9	6.6	16
173	From genes to therapy: the case of Philadelphia chromosome-positive leukemias. *Annals of the New York Academy of Sciences*, **2002**, 963, 306-12	6.5	7
172	Philadelphia-positive acute lymphoblastic leukemia with multiple subclones including duplication of the Philadelphia chromosome and Abelson oncogene. *Cancer Genetics and Cytogenetics*, **2002**, 132, 46-50		5

171	Detection of minimal residual disease in peripheral blood stem cells from two acute myeloid leukemia patients with trisomy 8 predicts early relapse after autologous bone marrow transplantation. *Cancer Genetics and Cytogenetics*, **2002**, 133, 98-101		5
170	Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. *Cancer*, **2002**, 94, 2416-25	6.4	52
169	Renal Hodgkin's disease. *British Journal of Haematology*, **2002**, 116, 732	4.5	1
168	Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype. *Leukemia*, **2002**, 16, 1745-51	10.7	29
167	Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. *Leukemia*, **2002**, 16, 2115-21	10.7	191
166	A 76-kb duplicon maps close to the BCR gene on chromosome 22 and the ABL gene on chromosome 9: possible involvement in the genesis of the Philadelphia chromosome translocation. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 9882-7	11.5	67
165	Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. *Leukemia*, **2002**, 16, 1176-81	10.7	90
164	Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma. *Leukemia*, **2002**, 16, 268-75	10.7	33
163	A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. *Blood*, **2002**, 99, 1527-35	2.2	147
162	Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. *New England Journal of Medicine*, **2002**, 346, 645-52	59.2	1693
161	A fourth case of BCR-FGFR1 positive CML-like disease with t(8;22) translocation showing an extensive deletion on the derivative chromosome 8p. *The Hematology Journal*, **2002**, 3, 315-6		31
160	Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one. *Haematologica*, **2002**, 87, 688-94; discussion 694	6.6	5
159	Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. *Blood*, **2001**, 98, 3074-81	2.2	275
158	MLL-AF6 fusion resulting from a new three-way translocation t(6;11;7) in a patient with acute myeloid leukemia. *Leukemia*, **2001**, 15, 1674-6	10.7	7
157	Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia. *Haematologica*, **2001**, 86, 252-9	6.6	29
156	Mutation of BAX occurs infrequently in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. *Genes Chromosomes and Cancer*, **2000**, 27, 177-82	5	9
155	Molecular profile of Epstein-Barr virus infection in HHV-8-positive primary effusion lymphoma. *Leukemia*, **2000**, 14, 271-7	10.7	53
154	The tyrosine kinase receptor met and its ligand HGF are co-expressed and functionally active in HHV-8 positive primary effusion lymphoma. *Leukemia*, **2000**, 14, 285-91	10.7	31

153	Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy. *Bone Marrow Transplantation*, **2000**, 25, 729-36	4.4	12
152	Novel type of BCR-ABL transcript in a chronic myelogenous leukaemia patient relapsed after bone marrow transplantation. *British Journal of Haematology*, **2000**, 111, 644-646	4.5	
151	Lack of SH3 domain does not imply a more severe clinical course in Ph+ chronic myeloid leukemia patients. *Blood*, **2000**, 95, 4019-4020	2.2	14
150	Common-variable immunodeficiency-related lymphomas associate with mutations and rearrangements of BCL-6: pathogenetic and histogenetic implications. *Human Pathology*, **2000**, 31, 871-3	3.7	20
149	The role of cytokines in the pathogenesis and management of AIDS-related lymphomas. *Leukemia and Lymphoma*, **2000**, 38, 481-8	1.9	18
148	Molecular pathogenesis of B-cell chronic lymphocytic leukemia: analysis of 13q14 chromosomal deletions. *Current Topics in Microbiology and Immunology*, **2000**, 252, 275-84	3.3	8
147	Novel type of BCR-ABL transcript in a chronic myelogenous leukaemia patient relapsed after bone marrow transplantation. *British Journal of Haematology*, **2000**, 111, 644-6	4.5	16
146	A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia. *Blood*, **2000**, 95, 96-101	2.2	33
145	Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. *Blood*, **2000**, 95, 651-9	2.2	133
144	The e19a2 bcr/abl breakpoint in acute lymphoblastic leukaemia. *British Journal of Haematology*, **2000**, 110, 493-6	4.5	6
143	HHV-8/KSHV is not associated with AIDS-related primary central nervous system lymphoma. *Brain Pathology*, **1999**, 9, 199-208	6	21
142	BCR/ABL mRNA and the P210BCR/ABL Protein Are Downmodulated by Interferon-? in Chronic Myeloid Leukemia Patients. *Blood*, **1999**, 94, 2200-2207	2.2	43
141	BCR/ABL rearrangement and leukemia phenotype. *Leukemia*, **1999**, 13 Suppl 1, S96	10.7	6
140	Concomitant expression of the rare E1/A3 and B2/A3 types of BCR/ABL transcript in a chronic myeloid leukemia (CML) patient. *Leukemia*, **1999**, 13, 1463-4	10.7	9
139	Translisin recognition site sequences flank translocation breakpoints in a Philadelphia chromosome positive chronic myeloid leukemia patient expressing a novel type of chimeric BCR-ABL transcript (E8-INT-A2). *Leukemia*, **1999**, 13, 1635-7	10.7	7
138	Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. *Leukemia*, **1999**, 13, 1901-28	10.7	920
137	Genetic characterization of HHV-8/KSHV-positive primary effusion lymphoma reveals frequent mutations of BCL6: implications for disease pathogenesis and histogenesis. *Genes Chromosomes and Cancer*, **1999**, 24, 16-23	5	81
136	A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia. *Haematologica*, **1999**, 84, 707-15	6.6	13

135	Hematopoietic growth factors in autologous transplantation. *Biotherapy (Dordrecht, Netherlands)*, **1998**, 10, 299-308		4
134	Patterns of cytokine expression in AIDS-related non-Hodgkin's lymphoma. *British Journal of Haematology*, **1998**, 103, 143-9	4.5	21
133	P230 BCR/ABL protein may be associated with an acute leukaemia phenotype. *British Journal of Haematology*, **1998**, 103, 1104-8	4.5	33
132	BCL-6 in aids-related lymphomas: pathogenetic and histogenetic implications. *Leukemia and Lymphoma*, **1998**, 31, 39-46	1.9	12
131	p53 mutation in a case of blastic transformation of follicular lymphoma with double bcl-2 rearrangement (MBR and VCR). *Leukemia and Lymphoma*, **1998**, 29, 595-605	1.9	14
130	Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients. *Annals of Oncology*, **1998**, 9, 55-61	10.3	77
129	Early Detection of Relapse by Prospective Reverse Transcriptase-Polymerase Chain Reaction Analysis of the PML/RARFusion Gene in Patients With Acute Promyelocytic Leukemia Enrolled in the GIMEMA-AIEOP Multicenter AIDATrial. *Blood*, **1998**, 92, 784-789	2.2	233
128	GAS6 Inhibits Granulocyte Adhesion to Endothelial Cells. *Blood*, **1998**, 91, 2334-2340	2.2	66
127	GAS6 Inhibits Granulocyte Adhesion to Endothelial Cells. *Blood*, **1998**, 91, 2334-2340	2.2	
126	Involvement of the bcl-6 gene in AIDS-related lymphomas. *Annals of Oncology*, **1997**, 8, S105-S108	10.3	6
125	Analysis of human herpesvirus type 8 infection in AIDS-related and AIDS-unrelated primary central nervous system lymphoma. *Journal of Infectious Diseases*, **1997**, 175, 1193-7	7	23
124	Molecular pathways in low grade B-cell lymphoma. *Leukemia and Lymphoma*, **1997**, 26 Suppl 1, 107-13	1.9	10
123	BCR/ABL transcripts and leukemia phenotype: an unsolved puzzle. *Leukemia and Lymphoma*, **1997**, 26, 281-6	1.9	17
122	Human herpesvirus type-8 (HHV-8) in haematopoietic neoplasia. *Leukemia and Lymphoma*, **1997**, 24, 257-66	1.9	32
121	Minimal residual disease in B-lymphoproliferative disorders by PCR detection of immunoglobulin heavy chain gene recombination. *Scandinavian Journal of Clinical and Laboratory Investigation*, **1997**, 57, 541-7	2	1
120	Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. *Genomics*, **1997**, 42, 369-77	4.3	107
119	Microsatellite instability in KSHV/HHV-8 positive body-cavity-based lymphoma. *Human Pathology*, **1997**, 28, 748-50	3.7	17
118	Biological determinants of long-term survival in chronic myelogenous leukemia patients treated with conventional chemotherapy. *Acta Haematologica*, **1997**, 97, 187-8	2.7	

117	Recommendations for the Molecular Diagnosis of Familial Adenomatous Polyposis. *Tumori*, **1997**, 83, 795-799	1.7	1
116	Genetic heterogeneity of AIDS-related small non-cleaved cell lymphoma. *British Journal of Haematology*, **1997**, 98, 726-32	4.5	12
115	Point mutations of the BCL-6 gene in Burkitt's lymphoma. *British Journal of Haematology*, **1997**, 99, 168-70	4.5	31
114	Detection of BCL-6 rearrangements and p53 mutations in Malt-lymphomas. *American Journal of Hematology*, **1997**, 56, 206-13	7.1	29
113	Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia. *Genes Chromosomes and Cancer*, **1997**, 19, 250-255	5	13
112	BCL-6 protein expression in AIDS-related non-Hodgkin's lymphomas: inverse relationship with Epstein-Barr virus-encoded latent membrane protein-1 expression. *American Journal of Pathology*, **1997**, 150, 155-65	5.8	44
111	Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. *Blood*, **1997**, 90, 1014-21	2.2	348
110	4-hydroxynonenal specifically inhibits c-myb but does not affect c-fos expressions in HL-60 cells. *Biochemical and Biophysical Research Communications*, **1996**, 227, 589-93	3.4	34
109	Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis. *Blood*, **1996**, 87, 1075-1080	2.2	98
108	Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction) [see comments]. *Blood*, **1996**, 88, 2410-2414	2.2	305
107	Distribution of human herpesvirus-8 sequences throughout the spectrum of AIDS-related neoplasia. *Aids*, **1996**, 10, 941-9	3.5	67
106	AIDS-related non-Hodgkin's lymphomas: molecular genetics, viral infection and cytokine deregulation. *Acta Haematologica*, **1996**, 95, 193-8	2.7	24
105	Persistence of E2A/PBX1 transcripts in t(1;19) childhood acute lymphoblastic leukemia: correlation with chemotherapy intensity and clinical outcome. *Leukemia Research*, **1996**, 20, 441-3	2.7	15
104	Distribution of TP53 mutations among acute leukemias with MLL rearrangements. *Genes Chromosomes and Cancer*, **1996**, 15, 48-53	5	9
103	Molecular heterogeneity of B-lineage diffuse large cell lymphoma. *Genes Chromosomes and Cancer*, **1996**, 16, 21-30	5	30
102	Analysis of microsatellite instability in chronic lymphoproliferative disorders. *Annals of Hematology*, **1996**, 72, 67-71	3	29
101	Kaposi's sarcoma-associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated lymphomatous effusions. *British Journal of Haematology*, **1996**, 94, 533-43	4.5	176
100	Analysis of microsatellite instability in chronic lymphoproliferative disorders **1996**, 72, 67		2

99	Interferon-alpha plus low-dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients. *European Journal of Haematology*, **1995**, 55, 184-8	3.8	8
98	Isochromosome 6p and deletion of 6q characterize two related cytogenetic clones in a patient with immunoblastic lymphoma. *Cancer Genetics and Cytogenetics*, **1995**, 81, 179-81		3
97	AIDS-related Burkitt's lymphoma. Morphologic and immunophenotypic study of biopsy specimens. *American Journal of Clinical Pathology*, **1995**, 103, 561-7	1.9	70
96	Polyclonal haemopoieses associated with long-term persistence of the AML1-ETO transcript in patients with FAB M2 acute myeloid leukaemia in continous clinical remission. *British Journal of Haematology*, **1995**, 90, 364-8	4.5	19
95	Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia. *British Journal of Haematology*, **1995**, 91, 625-9	4.5	50
94	Distribution of Kaposi's sarcoma herpesvirus sequences among lymphoid malignancies in Italy and Spain. *British Journal of Haematology*, **1995**, 91, 918-20	4.5	77
93	Genetic analysis of chromosome 13 deletions in BCR/ABL negative chronic myeloproliferative disorders. *Genes Chromosomes and Cancer*, **1995**, 14, 106-11	5	25
92	Repeated PCR in CML during IFN-alpha therapy. *European Journal of Haematology*, **1994**, 52, 152-5	3.8	5
91	Genetic analysis of p53 and RB1 tumor-suppressor genes in blast crisis of chronic myeloid leukemia. *Annals of Hematology*, **1994**, 68, 3-7	3	35
90	Molecular pathology of AIDS-related lymphomas. Biologic aspects and clinicopathologic heterogeneity. *Annals of Hematology*, **1994**, 69, 281-90	3	24
89	Human peripheral blood granulocytes and myeloid leukemic cell lines express both transcripts encoding for stem cell factor. *Stem Cells*, **1994**, 12, 521-6	5.8	7
88	Inhibition of c-myc expression induced by 4-hydroxynonenal, a product of lipid peroxidation, in the HL-60 human leukemic cell line. *Biochemical and Biophysical Research Communications*, **1994**, 203, 553-61	3.4	54
87	Restoration of normal polyclonal haemopoiesis in patients with chronic myeloid leukaemia autografted with Ph-negative peripheral stem cells. *British Journal of Haematology*, **1994**, 87, 867-70	4.5	23
86	Mobilization of cytogenetically 'normal' blood progenitors cells by intensive conventional chemotherapy for chronic myeloid and acute lymphoblastic leukemia. *Leukemia and Lymphoma*, **1993**, 9, 477-83	1.9	31
85	Molecular defects associated with the acute phase CML. *Leukemia and Lymphoma*, **1993**, 11 Suppl 1, 25-8	1.9	16
84	Molecular analysis of contiguous exons of the phenylalanine hydroxylase gene: identification of a new PKU mutation. *Journal of Medical Genetics*, **1993**, 30, 228-31	5.8	2
83	Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin?s lymphoma. *Blood*, **1993**, 81, 166-176	2.2	136
82	Preferential clustering of chromosomal breakpoints in Burkitt's lymphomas and L3 type acute lymphoblastic leukemias with a t(8;14) translocation. *Genes Chromosomes and Cancer*, **1993**, 8, 1-7	5	32

81	Recent advances in diagnosis of hemoglobinopathies. *Critical Reviews in Oncology/Hematology*, **1993**, 14, 89-105	7	2
80	The type of BCR/ABL junction does not predict the survival of patients with Ph1-positive chronic myeloid leukaemia. *British Journal of Haematology*, **1993**, 84, 265-8	4.5	18
79	Selective overshoot of Ph-negative blood hemopoietic cells after intensive idarubicin-containing regimen and their repopulating capacity after reinfusion. *Stem Cells*, **1993**, 11 Suppl 3, 67-72	5.8	13
78	Mutations in the P53 and RAS family genes are associated with tumor progression of BCR/ABL negative chronic myeloproliferative disorders. *Leukemia*, **1993**, 7, 946-53	10.7	31
77	Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. *Blood*, **1993**, 81, 166-76	2.2	23
76	Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin?s lymphoma. *Blood*, **1993**, 81, 166-176	2.2	174
75	Tumorigenic activity of a rearranged c-myc gene from a human T-cell leukemia line. *Carcinogenesis*, **1992**, 13, 883-5	4.6	2
74	Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. *Cancer Genetics and Cytogenetics*, **1992**, 64, 170-3		61
73	A new TaqI polymorphism in the p53 gene. *Nucleic Acids Research*, **1992**, 20, 928	20.1	26
72	Rapid identification by denaturing gradient gel electrophoresis of mutations in the gamma-globin gene promoters in non-deletion type HPFH. *British Journal of Haematology*, **1992**, 80, 533-8	4.5	28
71	Effect of IFN alpha therapy on secondary Ph1-positive clones. *British Journal of Haematology*, **1992**, 81, 451-3	4.5	1
70	Minimal residual disease status in transplanted chronic myelogenous leukemia patients: low incidence of polymerase chain reaction positive cases among 48 long disease-free subjects who received unmanipulated allogeneic bone marrow transplants. *Leukemia*, **1992**, 6, 507-12	10.7	29
69	Chronic neutrophilic leukaemia associated with polycythemia vera: pathogenetic implications and therapeutic approach. *British Journal of Haematology*, **1991**, 78, 286-8	4.5	20
68	A newly-characterized alpha-thalassaemia-1 deletion removes the entire alpha-like globin gene cluster in an Italian family. *British Journal of Haematology*, **1991**, 78, 529-34	4.5	20
67	c-erbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. *International Journal of Cancer*, **1991**, 47, 833-8	7.5	73
66	Analysis of N-ras gene mutations in medulloblastomas by polymerase chain reaction and oligonucleotide probes in formalin-fixed, paraffin-embedded tissues. *Medical and Pediatric Oncology*, **1991**, 19, 240-5		12
65	Simultaneous screening for beta-thalassemia mutations by chemical cleavage of mismatch. *Genomics*, **1991**, 11, 48-53	4.3	26
64	Trisomy 8 and an unbalanced t(5;17)(q11;p11) characterize two karyotypically independent clones in a case of idiopathic myelofibrosis evolving to acute nonlymphoid leukemia. *Cancer Genetics and Cytogenetics*, **1991**, 52, 63-9		6

63	Effect of recombinant human IL-3 on the mitotic index and karyotype of hemopoietic cells. *Cancer Genetics and Cytogenetics*, **1991**, 55, 235-41		4
62	Detection of Ph1-positive acute lymphoblastic leukaemia by PCR. GIMEMA Cooperative Study Group. *Lancet, The*, **1991**, 338, 958	40	7
61	Screening for mutations in the phenylalanine hydroxylase gene from Italian patients with phenylketonuria by using the chemical cleavage method: a new splice mutation. *American Journal of Human Genetics*, **1991**, 48, 631-5	11	24
60	The homozygous state for the -87 C----G beta + thalassaemia. *British Journal of Haematology*, **1990**, 75, 132-3	4.5	20
59	ABL proteins in Philadelphia-positive acute leukaemias and chronic myelogenous leukaemia blast crises. *British Journal of Haematology*, **1990**, 76, 39-44	4.5	10
58	Haplotype distribution and molecular defects of PKU in Italy. *Journal of Inherited Metabolic Disease*, **1990**, 13, 292-4	5.4	3
57	Haplotype distribution and molecular defects at the phenylalanine hydroxylase locus in Italy. *Human Genetics*, **1990**, 86, 69-72	6.3	15
56	Molecular and cytogenetic studies of a patient with Philadelphia-negative, BCR-positive chronic myeloid leukemia and t(12;12)(q13;p12). *Genes Chromosomes and Cancer*, **1990**, 1, 284-8	5	2
55	Molecular characterization of hereditary persistence of fetal hemoglobin in a patient from Cuba [letter]. *Blood*, **1990**, 76, 1262-1263	2.2	4
54	New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. *Blood*, **1990**, 76, 1819-1824	2.2	126
53	Immunoglobulin DNA Analysis as a Marker of Clonality in the Follow-up of Patients with Hairy Cell Leukemia Treated with Alpha-Interferon. *Leukemia and Lymphoma*, **1990**, 2, 103-10	1.9	
52	False-positive results with PCR to detect leukaemia-specific transcript. *Lancet, The*, **1990**, 335, 1037-8	40	53
51	Chromosome abnormalities involving heterochromatic regions in monocytic leukemia. *Cancer Genetics and Cytogenetics*, **1990**, 46, 99-106		3
50	New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. *Blood*, **1990**, 76, 1819-24	2.2	18
49	Molecular characterization of Ph' + hybrid acute leukemia. *Leukemia Research*, **1989**, 13, 1061-7	2.7	7
48	Molecular evidence of transient complete remission after autografting in Ph-/bcr rearranged chronic myelogenous leukaemia. *British Journal of Haematology*, **1989**, 72, 285-6	4.5	2
47	Immunoglobulin gene rearrangements in human multiple myeloma. *British Journal of Haematology*, **1989**, 73, 425	4.5	6
46	Cytogenetic and molecular studies in patients with chronic myeloid leukemia and variant Philadelphia translocations. *Cancer Genetics and Cytogenetics*, **1989**, 42, 191-201		17

45	Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features. *British Journal of Haematology*, **1988**, 69, 359-66	4.5	233
44	Cytogenetic and molecular analyses in Philadelphia chromosome positive acute lymphoblastic leukaemia. *British Journal of Haematology*, **1988**, 69, 424-6	4.5	2
43	Soluble factor(s) released by the PF-382 T-cell line enhances the stimulatory effect of monocytes on the BFU-E growth. *Journal of Cellular Physiology*, **1988**, 135, 127-32	7	5
42	Distribution of Ha-RAS-1 proto-oncogene alleles in breast cancer patients and in a control population. *Breast Cancer Research and Treatment*, **1988**, 11, 147-53	4.4	19
41	A frequent A gamma-hereditary persistence of fetal hemoglobin in northern Sardinia: its molecular basis and hematologic phenotype in heterozygotes and compound heterozygotes with beta-thalassemia. *Human Genetics*, **1988**, 79, 13-7	6.3	23
40	Multilineage cell involvement in Ph1-negative, bcr-negative chronic myeloid leukemia. *Leukemia Research*, **1988**, 12, 637-45	2.7	1
39	Meiotic recombination in the beta globin gene cluster causing an error in prenatal diagnosis of beta thalassaemia. *Journal of Medical Genetics*, **1988**, 25, 307-10	5.8	5
38	Variability of the molecular defects corresponding to the presence of a Philadelphia chromosome in human hematologic malignancies. *Blood*, **1988**, 72, 1203-1208	2.2	37
37	Delineation of specific beta-thalassemia mutations in high-risk areas of Italy: a prerequisite for prenatal diagnosis. *Blood*, **1988**, 71, 983-988	2.2	21
36	Germ-line configuration of the T-cell receptor beta-chain gene in B-cell chronic lymphoproliferative disorders which co-express T-cell antigens. *European Journal of Haematology*, **1987**, 39, 412-7	3.8	4
35	Duplication of Ph and of 9q+ chromosomes during the blastic transformation of a CML case. *Cancer Genetics and Cytogenetics*, **1987**, 29, 57-63		4
34	Significance of the Philadelphia chromosome in acute leukemias: variable correlation with rearrangements involving the c-abl and bcr genes. *Annals of the New York Academy of Sciences*, **1987**, 511, 270-6	6.5	
33	A novel type of c-myc translocation in a T lymphoma cell line. *Annals of the New York Academy of Sciences*, **1987**, 511, 338-42	6.5	2
32	Sardinian delta beta zero-thalassemia: a further example of a C to T substitution at position -196 of the A gamma globin gene promoter. *Blood*, **1987**, 69, 1058-1061	2.2	25
31	7q-and loss of a polymorphism for the met oncogene in a patient with myelofibrosis. *Cytotechnology*, **1987**, 1, 37-40	2.2	
30	A benign form of thalassaemia intermedia may be determined by the interaction of triplicated □ locus and heterozygous □thalassaemia. *British Journal of Haematology*, **1987**, 66, 103-107	4.5	21
29	Sardinian delta beta zero-thalassemia: a further example of a C to T substitution at position -196 of the A gamma globin gene promoter. *Blood*, **1987**, 69, 1058-61	2.2	7
28	□Thalassemic Syndromes As a Model for the Study of the Molecular Basis of Human Inherited Disease **1987**, 283-293		

27	Fetal diagnosis of beta-thalassaemia by DNA analysis in Italy. *Lancet, The*, **1986**, 1, 390	40	4
26	3' c-myc rearrangement in a human leukemic T-cell line. *Cancer Research*, **1986**, 46, 1413-7	10.1	18
25	Heterogeneity of delta, beta-thalassemia and hereditary persistence of Hb F in the Mediterranean area. *Annals of the New York Academy of Sciences*, **1985**, 445, 170-6	6.5	
24	A molecular study of a family with Greek hereditary persistence of fetal hemoglobin and beta-thalassemia.. *EMBO Journal*, **1984**, 3, 2641-2645	13	72
23	The beta-globin gene in Sardinian delta beta 0-thalassemia carries a C--T nonsense mutation at codon 39.. *EMBO Journal*, **1984**, 3, 785-787	13	10
22	The beta-globin gene in Sardinian delta beta 0-thalassemia carries a C----T nonsense mutation at codon 39. *EMBO Journal*, **1984**, 3, 785-7	13	4
21	A molecular study of a family with Greek hereditary persistence of fetal hemoglobin and beta-thalassemia. *EMBO Journal*, **1984**, 3, 2641-5	13	40
20	Fetal haemoglobin synthesis following fetal liver transplantation in man. *British Journal of Haematology*, **1983**, 55, 609-14	4.5	6
19	Molecular comparison of delta beta-thalassemia and hereditary persistence of fetal hemoglobin DNAs: evidence of a regulatory area?. *Proceedings of the National Academy of Sciences of the United States of America*, **1982**, 79, 2347-51	11.5	68
18	Preferential induction of fetal versus embryonic globin chains in human leukemic cell lines. *Leukemia Research*, **1982**, 6, 155-63	2.7	6
17	G gamma and a gamma globin chain synthesis in bone marrow and peripheral blood of beta-thalassaemia homozygotes. *British Journal of Haematology*, **1982**, 52, 225-31	4.5	4
16	High Hb F levels in a Sardinian family: a genetic defect intermediate between HPFH Greek type and delta beta-thalassemia?. *Haematologica*, **1982**, 67, 499-507	6.6	2
15	gamma chain composition in five Italian newborns heterozygous for Hb F Malta G gamma-117 His leads to Arg. *British Journal of Haematology*, **1980**, 44, 93-9	4.5	3
14	Analysis of the gamma chains in a homozygote for HPFH Negro type and in three related heterozygotes. *Acta Haematologica*, **1980**, 63, 146-50	2.7	
13	Polymorphism of human fetal haemoglobin studied by isoelectric focusing. *FEBS Letters*, **1980**, 115, 68-70	3.8	8
12	Polymorphism of human gamma-globin genes in Mediterranean populations. *Nature*, **1979**, 282, 316-8	50.4	15
11	Genetic studies on some Nepalese populations. *Journal of Human Evolution*, **1979**, 8, 385-397	3.1	3
10	Electrophoretic separation of A gamma and G gamma human globin chains in Nonidet P-40. *Clinica Chimica Acta*, **1979**, 99, 7-11	6.2	14

9	G gamma and A gamma globin chains separation and quantitation by isoelectric focusing. *Biochemical and Biophysical Research Communications*, **1979**, 87, 1-8	3.4	61
8	Human T gamma globin chain is a variant of A gamma chain (A gamma Sardinia). *Proceedings of the National Academy of Sciences of the United States of America*, **1979**, 76, 3420-4	11.5	51
7	Composition of the γ-Chains of Human Fetal Hemoglobin at Birth and during Intrauterine Life. *Acta Haematologica*, **1979**, 62, 45-50	2.7	2
6	Biosynthetic studies and gamma-chain composition in the Greek type of hereditary persistence of fetal hemoglobin and in its association with beta-thalassemia. *Acta Haematologica*, **1979**, 61, 272-7	2.7	1
5	Clinical and haematological data in 254 cases of beta-thalassaemia trait in Italy. *British Journal of Haematology*, **1976**, 33, 91-9	4.5	37
4	Significance of a new type of human fetal hemoglobin carrying a replacement isoleucine replaced by threonine at position 75)E 19) of the gamma chain. *Human Genetics*, **1976**, 32, 305-13	6.3	102
3	The relationship between anemia, fecal stercobilinogen, erythrocyte survival, and globin synthesis in heterozygotes for beta-thalassemia. *Blood*, **1975**, 46, 693-698	2.2	21
2	Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. *Leukemia*,13, 1901-1928	10.7	62
1	Concamitant expression of the rare E1/A3 and B2/A3 types of BCR/ABL transcript in a chronic myeloid leukemia (CML) patient. *Leukemia*,13, 1463-1464	10.7	